Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Deffered Revenue (2020)

Ovid Therapeutics (OVID) has disclosed Non-Current Deffered Revenue for 1 consecutive years, with $10.2 million as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Non-Current Deffered Revenue changed N/A year-over-year to $10.2 million, compared with a TTM value of $10.2 million through Dec 2020, changed N/A, and an annual FY2020 reading of $10.2 million, changed N/A over the prior year.
  • Non-Current Deffered Revenue was $10.2 million for Q4 2020 at Ovid Therapeutics, up from $9.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $10.2 million in Q4 2020 and bottomed at $9.9 million in Q3 2020.